On October 21, 2024, the Division of Examinations of the Securities and Exchange Commission (SEC) released its much-anticipated 2025 examination priorities. This announcement serves as a crucial guide for registered investment advisers, investment companies, and broker-dealers, highlighting areas under scrutiny for the upcoming year. Despite the potential for shifts in focus due to a changing presidential administration, many core enforcement areas are expected to remain consistent.

Key areas of focus include conflicts of interest disclosures, compliance with Regulation Best Interest (Reg BI), cybersecurity, and the growing impact of artificial intelligence and crypto assets. The Division’s emphasis on these areas signals its commitment to maintaining rigorous standards in the financial sector.

Investment Advisers

The Division maintains its tradition of prioritizing examinations for investment advisers who have never been examined, newly-registered advisers, and those not recently reviewed. The focus for 2025 will be on fiduciary standards, compliance programs, and private fund advisers.

Fiduciary Duties

Investment advisers must adhere to fiduciary standards of conduct, acting in the best interests of their clients. The Division will pay close attention to advice on high-cost products, unconventional instruments, and assets sensitive to market changes, such as commercial real estate.

Compliance Programs

Compliance with Rule 206(4)-7 under the Investment Advisers Act of 1940 remains a priority. This includes adopting and implementing compliance policies, designating a chief compliance officer, and conducting annual reviews. The Division will evaluate core compliance areas, including marketing, valuation, and portfolio management.

Broker-Dealers

The SEC has previously taken action against broker-dealers for Reg BI violations and Form CRS obligations. In 2025, these remain top priorities, along with financial responsibility and trading-related practices.

Regulation Best Interest

Broker-dealers must ensure recommendations are in the best interests of their clients. The Division will assess conflict of interest disclosures and practices for identifying, mitigating, and eliminating conflicts.

Form CRS

Broker-dealers are required to provide Form CRS to all retail investors. The Division will review the content of these relationship summaries for accuracy and completeness.

Risk Areas

Cybersecurity, compliance with recent regulatory amendments, financial technologies, and crypto assets are highlighted as presenting the highest risks to investors and markets.

Cybersecurity

The Division will focus on registrant practices to prevent service interruptions and protect investor information, emphasizing policies, governance, and incident response.

Financial Technologies

With the rise of AI, the 2025 priorities emphasize the use of automated investment tools and digital engagement practices. The Division will assess how AI is implemented and monitored.

For more detailed insights, you can refer to the original article by Eric Mikkelson and Carissa Occhipinto at Stinson LLP.

More Articles

Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!

The Remote Work Revolution: Redefining Real Estate

Imagine a morning where the commute is just a few steps from your bedroom to your home office. This is the reality for many in today's post-pandemic world, where remote work has become a staple of the modern workforce.

By |December 2, 2024|Categories: Article, Real Estate, Remote Work|Tags: , |0 Comments

CRISPR: The Future of Gene Editing and Its Clinical Implications

CRISPR technology has become the frontrunner in genome editing, surpassing earlier methods like zinc finger nucleases and transcription activator-like effector nucleases. The recent FDA approval of the CRISPR-Cas9 drug, exa-cel, marks a significant milestone particularly for treating sickle cell disease and transfusion-dependent beta thalassemia.

By |December 1, 2024|Categories: Article, Biotechnology, Medicine|Tags: , |0 Comments

AI Revolution in Oncology: Transformative Potential or Overhyped?

In recent years, artificial intelligence has emerged as a revolutionary tool in the field of oncology. AI's integration into healthcare transcends buzzwords, transforming cancer diagnosis, treatment personalization, and drug discovery.

AI in Radiology: A Double-Edged Sword

The rapid advancements in artificial intelligence (AI) are transforming the landscape of radiology, promising to enhance diagnostic accuracy and support personalized medicine. However, as this technology becomes more integral to medical imaging, it brings with it a host of ethical and societal considerations that cannot be ignored.

Humanity at the Crossroads: Ethical Implications of AI in Medicine

AI's promise in healthcare is undeniable, with its ability to uncover hidden disease patterns and predict illnesses. However, the reliance on historical data can exacerbate existing biases, particularly affecting marginalized communities such as the LGBTQIA+ and certain ethnic and racial groups.

The Future of Telemedicine: Challenges and Opportunities Beyond the Pandemic

Telemedicine stands out as a transformative force, offering a lifeline to patients and providers alike. As we move beyond the pandemic, the challenge is to integrate this technology without escalating costs or overshadowing the indispensable role of in-person consultations.

By |November 30, 2024|Categories: Article, Healthcare, Technology|Tags: , |0 Comments